About CYPRESS

We are researching the investigational drug (ampreloxetine) in the Phase 3 CYPRESS trial to confirm whether the investigational drug is effective and safe in treating nOH symptoms in patients with MSA and to learn about any unwanted side effects.

CYPRESS

An ampreloxetine study for nOH in patients with MSA

Theravance Biopharma
Medicines That Make a Difference®

More Information :

www.cypress-study.com

+1-855-633-8479

cypress@theravance.com

You can also learn more by visiting:
www.clinicaltrials.gov/study/NCT05696717

The Phase 3 CYPRESS Clinical Trial

NOW ENROLLING!



Why Participate?

We're taking another critical step toward the goal of neurogenic orthostatic hypotension (nOH) symptom relief in patients with multiple system atrophy (MSA).

Symptomatic nOH affects approximately 70-90% of those with MSA, with symptoms such as dizziness, light-headedness, and feeling faint interfering with one's ability to perform daily activities — especially those requiring standing or walking.

The Phase 3 trial involves 9 visits over a 20-week study treatment period, followed by an optional 2-year long-term extension in which all participants receive the investigational drug. Participants may be eligible to participate in the study remotely (e.g., from your home) after an initial in-office study visit.

Please contact us directly to explore how we might address your specific situation. We'd love to hear from you!

CYPRESS

Have you been diagnosed with **multiple system atrophy (MSA)** and have dizziness symptoms associated with **neurogenic orthostatic hypotension (nOH)**? If so, you may qualify.

Scan the QR code above or visit **www.cypress-study.com** for more information regarding trial participation. You can also contact us directly at **+1-855-633-8479**.

What to Expect:

Study Highlights

- Once daily, single tablet
- All participants receive the investigational drug during the 12-week open-label period, followed by an 8-week treatment with either placebo or investigational drug

Duration of Study

- 20-week study treatment period
- Participants who remain in the study will receive the investigational drug for up to 2 years as part of a long-term extension of the study

Study Visits

- Simple evaluations (similar to regular checkups with questionnaires)
- Only 9 visits in the treatment period

**Ampreloxetine is not currently approved by any health agency for use in treating symptoms of nOH in patients with MSA.*